新加坡的一项基金投资在一家开发抗老化疗法的生物技术公司,计划于2025年底进行人类试验。 A Singapore fund invested in a biotech firm developing anti-aging therapies, with a human trial planned for late 2025.

以新加坡为基地的长寿基金 " 永生龙 " 投资于 " 无限生物 " ,这是一家生物技术公司,开发多目标治疗方法,以克服老龄化问题。 Immortal Dragons, a Singapore-based longevity fund, has invested in Unlimited Bio, a biotech company developing multi-targeted therapies to combat aging. 该公司的平台将基因疗法、生物学和其他处理方法结合起来,以解决相互关联的生物系统。 The company’s platform combines gene therapies, biologics, and other treatments to address interconnected biological systems. 初始候选人包括VEGF-A、Follistatin、Al-Klotho和BDNF, VEGF-A显示血管健康显著改善,安全记录良好。 Initial candidates include VEGF-A, Follistatin, α-Klotho, and BDNF, with VEGF-A showing significant improvement in vascular health and a strong safety record. 计划在2025年底至2026年初在使用替代端点的特别经济区进行人类第一次临床试验试验,对健康志愿者进行双重基因治疗组合,但需获得管制批准。 A first-in-human clinical trial testing a dual gene therapy combination in healthy volunteers is planned for late 2025 to early 2026, pending regulatory approval, in a Special Economic Zone using surrogate endpoints. 这场试验旨在验证协同恢复活力的效果,支持永生龙在工程驱动的延长寿命方面的更广泛战略。 The trial aims to validate synergistic rejuvenation effects, supporting Immortal Dragons’ broader strategy in engineering-driven life extension.